Mood Stabilizers and Anxiolytic Medications

Core Idea

Mood stabilizers (lithium, anticonvulsants, atypical antipsychotics) stabilize mood cycling in bipolar disorder through diverse mechanisms; lithium's mechanism remains incompletely understood but involves second-messenger modulation. Anxiolytics (benzodiazepines) enhance GABAergic inhibition and are highly effective for acute anxiety but carry dependence and abuse risks, limiting long-term use. Buspirone, antihistamines, and other alternatives offer lower dependence potential but slower onset.

Explainer

You know that bipolar disorder involves cycling between manic and depressive episodes driven by dysregulation of mood and arousal. You know that anxiety disorders involve excessive, persistent fear or worry that interferes with functioning. You also have a foundation in how drugs interact with receptors and second messengers. Mood stabilizers and anxiolytics are the primary pharmacological tools for these conditions, but their mechanisms differ substantially — and understanding those mechanisms illuminates both their benefits and their risks.

Lithium is the original mood stabilizer, used clinically since the 1950s and still first-line for bipolar I. Its mechanism remains only partially understood: it is thought to interfere with the inositol phosphate (IP3) signaling pathway and to inhibit glycogen synthase kinase-3 (GSK-3), a kinase involved in synaptic plasticity and neuroprotection. Whatever the mechanism, lithium reduces both the frequency and severity of mood episodes. Its clinical challenge is its narrow therapeutic window — the blood level that works is close to the level that is toxic (tremor, nausea, renal and thyroid effects at toxic doses). Regular blood monitoring is essential. Anticonvulsants like valproate and lamotrigine act partly by blocking voltage-gated sodium channels, stabilizing neural membrane excitability — the same target exploited to prevent seizures, which share with mania a quality of excess neural discharge. Atypical antipsychotics (e.g., quetiapine, olanzapine) add dopamine and serotonin receptor blockade and are used adjunctively, particularly for acute manic episodes.

Benzodiazepines are the prototypical anxiolytics. They bind to a modulatory site on the GABA-A receptor (distinct from GABA's own binding site), increasing the *frequency* of chloride channel opening in response to GABA — not the duration (that is the barbiturate mechanism). Enhanced chloride influx hyperpolarizes neurons across the brain, producing anxiolytic, sedative, anticonvulsant, and muscle-relaxant effects. Critically, benzodiazepines are positive allosteric modulators — they don't activate GABA-A receptors independently, they enhance the response to GABA itself. This creates a ceiling effect and explains why, at high doses, they are far safer than barbiturates. The problem is tolerance and dependence: chronic use downregulates GABA-A receptor sensitivity, requiring escalating doses, and abrupt discontinuation can cause rebound anxiety, insomnia, and in severe cases, life-threatening seizures.

Buspirone offers an alternative mechanism for chronic anxiety management: it is a partial agonist at serotonin 5-HT1A receptors, without GABA effects and without dependence or sedation. Its disadvantage is onset — 2 to 4 weeks before therapeutic effect, making it useless for acute anxiety and often poorly accepted by patients who have experienced benzodiazepine's rapid relief. This contrast illustrates a central tension in psychopharmacology: the fastest-acting treatments tend to have the highest abuse liability. Rational prescribing requires matching agent to clinical context — acute panic warrants different management than generalized anxiety disorder being treated long-term, where the dependence risk of chronic benzodiazepine use becomes the dominant concern.